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Abstract
Suppression of ovarian tumor growth by chromosome
3p was demonstrated in a previous study. Deleted in
Lung and Esophageal Cancer 1 (DLEC1) on 3p22.3
is a candidate tumor suppressor in lung, esophageal,
and renal cancers. The potential involvement of DLEC1
in epithelial ovarian cancer remains unknown. In the
present study, DLEC1 downregulation was found in
ovarian cancer cell lines and primary ovarian tumors.
Focus-expressed DLEC1 in two ovarian cancer cell
lines resulted in 41% to 52% inhibition of colony for-
mation. No chromosomal loss of chromosome 3p22.3
in any ovarian cancer cell line or tissue was found. Pro-
moter hypermethylation ofDLEC1wasdetected in ovar-
ian cancer cell lines with reduced DLEC1 transcripts,
whereas methylation was not detected in normal ovar-
ian epithelium and DLEC1-expressing ovarian cancer
cell lines. Treatment with demethylating agent en-
hanced DLEC1 expression in 90% (9 of 10) of ovarian
cancer cell lines. DLEC1 promoter methylation was ex-
amined in 13 high-grade ovarian tumor tissues with
DLEC1 downregulation, in which 54% of the tumors
showedDLEC1methylation. In addition, 80% of ovarian
cancer cell lines significantly upregulated DLEC1 tran-
scripts after histone deacetylase inhibitor treatment.
Therefore, our results suggested that DLEC1 sup-
pressed the growth of ovarian cancer cells and that its
downregulation was closely associated with promoter
hypermethylation and histone hypoacetylation.
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Introduction
Ovarian cancer ranks as the fifth leading cause of cancer
deaths in women and has the highest mortality rate among
gynecologic malignancies in the United States [1]. Although
ovarian cancer susceptibility genes (e.g., BRCA1, BRCA2, and
MSH2) have been identified [2,3], most cases are sporadic
and somatic mutations in familial ovarian cancer genes are not
a major feature of sporadic cancers. Loss of heterozygosity
(LOH) involving several chromosome 3p regions, accompanied
by chromosome 3p deletions, is frequently detected in many
common sporadic cancers, including lung, breast, cervical,
kidney, and head and neck cancers [4]. These 3p genetic
alterations lead to the assumption that the short arm of human
chromosome 3 may harbor several tumor-suppressor genes.
In ovarian cancer, LOH on chromosome 3p has also been
reported to occur at a frequency ranging from 38% to 52%
[5–8], and several common LOH regions on chromosome 3
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have been mapped, including 3p12–p13, 3p14.2, 3p21.1–
p22, 3p24–p25, and 3p25–p26 [6–8]. Functional study
demonstrated that microcell-mediated chromosomal transfer
of chromosome 3 into an ovarian cancer cell line induced se-
nescence, growth arrest, and suppression of tumorigenicity
[9]. Multiple lines of evidence suggested that chromosome
3p might harbor tumor-suppressor genes in ovarian cancer.
However, FHIT and VHL, two well-known tumor-suppressor
genes located on 3p, are not commonly inactivated in ovar-
ian carcinogenesis [10,11]. RASSF1A, located on 3p21.3,
has been suggested as a new candidate tumor-suppressor
gene in human cancers. Epigenetic silencing of RASSF1A
was detected in 40% of ovarian cancer cell lines and tumor
tissues [12–14]. These data suggested thatRASSF1A is one
of 3p candidate tumor suppressors in ovarian cancer. Re-
cently, a gene located on chromosome 3p22.3, named De-
leted in Lung and Esophageal Cancer 1 (DLEC1), has been
discovered as a candidate tumor- suppressor gene in lung,
esophageal, and renal cancers [15]. The DLEC1 gene con-
tains 37 exons and spans approximately 59 kb. The predicted
DLEC1 protein contains 1755 amino acids. However, its
exact biologic function is still unclear because the pre-
dicted amino acid sequence of DLEC1 has no significant
homology to any of the known proteins or domains [15]. Here
we speculate the possible involvement of DLEC1 in ovarian
cancer pathogenesis by evaluating the tumor-suppressing
activity of DLEC1 and by delineating the mechanisms that
are related to DLEC1 downregulation in ovarian cancer.
Materials and Methods
Cell Lines, Cultures, and Tumor Specimens
Five primary cultures of normal human ovarian sur-
face epithelium (HOSE) cells (HOSE2177, HOSE0706,
HOSE2105, HOSE2107, and HOSE2170) were used in
this study. These ovarian epithelial cells are scraped from
the surface of the ovary in patients with benign gynecologic
diseases. Five HOSE samples (HOSE1912, HOSE2085,
HOSE2225, HOSE2237, and HOSE2270) were collected
directly from ovarian epithelial brushing. Twelve ovarian can-
cer cell lines (CaOV3, DOV13, MCAS, OVCA3, OVCA420,
OVCA429, OVCA432, OVCA433, OVCA633, PEO4, SKOV3,
and TOV112D) were used. All ovarian cancer cell lines were
obtained either by recovery of material from ascites or by pro-
curement of explanted tissue from solid tumors, as described
previously [16]. They were either established in the Labora-
tory of Gynecologic Oncology, Brigham and Women’s Hos-
pital (Boston, MA), or purchased from the American Type
Culture Collection (Rockville, MD) and the Japanese Col-
lection of Research Bioresources (Tokyo, Japan). In addition,
91 cases of primary ovarian tumor tissues [25 serous tumors
with low malignant potential (LMP), 6 low-grade (grade 1,
late stage) serous carcinomas, and 60 high-grade (grades 2
and 3, late stage) serious carcinomas] were included in
the study. All patient-derived specimens were collected
and archived under protocols approved by the Institutional
Review Board.
Real-Time Quantitative Reverse Transcription
Polymerase Chain Reaction (PCR)
Two micrograms of total RNA obtained from 5 primary
cultures of HOSE cell lines and 12 ovarian cancer cell lines
was reverse-transcribed to cDNA using TaqMan reverse
transcription reagents (Applied Biosystems, Foster City,
CA). Fifteen nanograms of total RNA obtained from 91
microdissected ovarian tumor tissues and 5 HOSE-scraped
samples was amplified and reverse-transcribed by the
Ovation Aminoallyl RNA amplification and labeling system
(NuGEN Technologies, Inc., San Carlos, CA). The PCR
primers used were 5V-GAC GAA GTG AGC GCA AGC-3V
(forward) and 5V-ATC CAG CCG CTG CTT ATA GA-3V
(reverse) for DLEC1, and 5V-CGC GAG AAG ATG ACC
CAG AT-3V (forward) and 5V-GTA CGG CCA GAG GCG
TAC AG-3V (reverse) for b-actin. Using SYBP Green PCR
master mix (Applied Biosystems), PCR products were ana-
lyzed by the 7300 real-time PCR system (Applied Biosys-
tems). All reactions were performed in triplicate. The relative
DLEC1 mRNA level of each sample was normalized with
b-actin and calculated using 2(DDCT) [17] by comparing the
amount of mRNA of each sample to a HOSE sample.
Anchorage-Dependent Colony Formation Assay
Anchorage-dependent colony formation assay was per-
formed by pcDNA3.1+ transfection of either a plasmid con-
taining full-length DLEC1 cDNA (a gift from Dr. Y Nakamura)
[15] or an empty vector (pcDNA3.1+) in ovarian cancer cells
OVCA429 and OVCA432 using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA). After transfection, cells were then split
and grown in medium containing 500 mg/ml Geneticin (Invi-
trogen) for 10 days. Colonies were stained with crystal violet
and counted. The transfection experiment was performed in
triplicate and repeated twice.
Concurrent Analysis of LOH and Copy Number
Abnormality (CNA) on Chromosome 3
LOH and CNA of chromosome 3 in ovarian cancer cell
lines were analyzed by the Affmetrix 10K SNP mapping
array [18]. Briefly, genomic DNA of 11 human ovarian cancer
cell lines was isolated using a Qiagen DNeasy kit (Qiagen
GmbH, Hilden, Germany). A total of 250 ng of purified DNA
was digested with XbaI, ligated to an adaptor, PCR-amplified,
fragmented, and biotin-labeled according to the Affmetrix
Single Primer Assay protocol. Subsequently, biotin-labeled
DNA was hybridized to the Affmetrix 10K SNPmapping array.
Image acquisition and data analysis were performed as pre-
viously described [18].
Determination of DLEC1 Copy Number by Real-Time
Quantitative PCR
Genomic DNA (100 ng/ml) of peripheral blood lympho-
cytes (PBL) from healthy subjects, HOSE, and ovarian
cancer cell lines were used to determine DNA copy number
by quantitative PCR. The primers for the DLEC1 locus
(STS marker SHGC-170056) were 5V-AGT GGG GAT TCA
GCA GTG AATAA-3V and 5V-ATG TGA GTC TGA AGT TCA
AGG GC-3V. Using SYBP Green PCR master mix (Applied
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Biosystems), PCR products were analyzed by the 7300
real-time PCR system (Applied Biosystems). Relative gene
copy numbers were derived using the formula: 2DCT, where
DCT is the difference in amplification cycles required to
detect amplification products from equal starting concen-
trations of normal genomic DNA compared to tumor geno-
mic DNA [19]. All assays were performed in triplicate.
Quantitative PCR results were normalized to the D2S385
locus, which was chosen because it was located in a region
of the genome that did not show any alterations in human
ovarian tumors [20]. The primers for D2S385 were 5V-AGC
TGT CAG TAG AAA TAA GCA GAG A-3V and 5V-TCA ATA
ACA CGC CAA AAG AC-3V. Besides D2S385, Line-1 loci
(M80343) on the genome also served as controls for nor-
malization. The primers for the Line-1 gene were 5V-AAA
GCC GCT CAA CTA CAT GG-3V and 5V-TGC TTT GAATGC
GTC CCA GAG-3V [21].
Methylation-Specific PCR (MSP)
CpG islands of the DLEC1 promoter were identified by CpG
Island Searcher (http://ccnt.hsc.usc.edu/cpgislands/) using the
following criteria: GC content >55%, ObsCpG/ExpCpG >0.65,
and minimum length >500 bp. Genomic DNA were bisulfite-
modified by CpGenome DNA Modification kit (Chemicon
International, Temecula, CA). MSP was performed on bisulfite-
modified DNA using primer sequences for methylated reac-
tions [5V-GAT TAT AGC GAT GAC GGG ATT C-3V (forward)
and 5V-ACC CGA CTA ATA ACG AAA TTA ACG-3V (reverse)]
and unmethylated reactions [5V-TGATTATAG TGATGATGG
GAT TTG A-3V (forward) and 5V-CCC AAC TAATAA CAA AAT
TAA CAC C-3V (reverse)]. The annealing temperature of both
methylated and unmethylated reactions was 60jC, and both
PCR products were 197 bp in size.
Bisulfite Sequencing
The bisulfite-modified DNA of ovarian cancer cell lines
was prepared for bisulfite sequencing. To obtain products
for sequencing, PCR amplification was performed on 100 ng
of bisulfite-modified genomic DNA. The PCR primers used
were 5V-ATT TTT AAA AGG ATA ATG TTG AAG ATA TA-3V
(forward) and 5V-TAA ACT AAC TAA AAC TAC TAA ACC
C-3V (reverse). The annealing temperature was 58jC, and
the PCR product size was 255 bp. Eighteen CpG sites
were located within the PCR product. Amplification frag-
ments were cloned. Eight to 10 clones of each sample were
sequenced by the Biopolymers Facility at Harvard Medical
School (Boston, MA).
5-Aza-2 V-Deoxycytidine (AZA) and Trichostatin A
(TSA) Treatment
For AZA treatment, ovarian cancer cells, which showed
DLEC1 downregulation, were incubated in 0 and 1 mM AZA
for 4 days (Sigma-Aldrich, Inc., St. Louis, MO). The medium
and the drug were replaced every 24 hours. For TSA treat-
ment, the cells were incubated with 0 and 500 ng/ml TSA
(Sigma-Aldrich, Inc.) for 24 hours. After AZA and TSA treat-
ments, total RNA and genomic DNA were collected.
Chromatin Immunoprecipitation (ChIP)
ChIP assays were carried out using the ChIP assay kit
(Upstate, Charlottesville, VA). Briefly, chromatin in TSA-
treated or untreated ovarian cancer cells was crosslinked
by adding formaldehyde directly to the culture medium to a
final concentration of 1% and incubated for 10 minutes at
37jC. Cells were washed twice using ice-cold phosphate-
buffered saline with protease inhibitors. The cells were
scraped, collected, and pelleted for 4 minutes at 2000 rpm
at 4jC. Cell pellets were resuspended to 1  106 cells/200 ml
of sodium dodecyl sulfate lysis buffer with protease inhibi-
tors and incubated on ice for 10 minutes. Lysates were
sonicated to shear DNA to an average length between
200 and 1000 bp. Then the samples were centrifuged for
10 minutes at 13,000 rpm at 4jC, and the supernatant was
transferred to a new tube. A sonicated cell supernatant was
diluted 10-fold in ChIP dilution buffer with protease inhibitors.
A diluted cell supernatant (2 ml) was precleared with 75 ml
of salmon sperm DNA/protein A agarose 50% slurry for
30 minutes at 4jC with agitation. Agarose was pelleted by
brief centrifugation, and the supernatant was transferred
into a new tube. Primary antibodies (anti–acetyl-histones
H3 and H4, catalog nos. 06-599 and 06-866; Upstate) were
added to the precleared 2-ml supernatant and incubated
overnight at 4jC. Antibody/histone complexes were col-
lected by adding 60 ml of salmon sperm DNA/protein A
agarose slurry for 1 hour at 4jC with rotation. The agarose
was pelleted by gentle centrifugation.
The protein A agarose/antibody/chromatin complex was
further washed by a series of washing buffers. Immunocom-
plexes were eluted and reverse-crosslinked. Immunopreci-
pitated DNA was recovered by phenol/chloroform extraction
and analyzed by PCR. The primer pairs used for ChIP
analysis of the DLEC1 promoter region were 5V-ACA ATG
ACC ACA GCG ATG AC-3V (forward) and 5V-GCT GTA GTG
GAA GGC CTC AG-3V (reverse). PCR was performed for
30 to 33 cycles, the annealing temperature was 65jC, and
the PCR product size was 275 bp.
Statistical Analysis
Quantitative PCR data were compared using either non-
parametric Mann-Whitney U test or Kruskal-Wallis test. The
level of critical significance was set at P < .05. All analyses
were performed using SPSS version 10.0 (SPSS, Inc.,
Chicago, IL).
Results
DLEC1 Downregulation in Epithelial Ovarian Cancers
DLEC1 has been implicated as a candidate tumor sup-
pressor located on chromosome 3p22.3 and has been
shown to be downregulated in lung, esophageal, and renal
cancers [15]. We attempted to examine the expression level
of DLEC1 mRNA in normal HOSE cell lines, ovarian cancer
cell lines, and ovarian tumor tissues. Because there are at
least six alternative transcripts of DLEC1 in normal and can-
cer cells [15], we designed a primer set that flanks exons 1
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and 2 and detected all DLEC1 transcripts. DLEC1 expres-
sion levels in ovarian cancer cell lines are lower than those in
normal HOSE cell lines (P = .027) (Figure 1A). DLEC1
downregulation was also found in serous tumors of LMP,
low-grade serous cancers, and high-grade serous cancers
(Figure 1B). DLEC1 expression levels were significantly
different among normal HOSE tumors, LMP tumors, low-
grade serous cancers, and high-grade serous cancers (P =
.001) (Figure 1C); between HOSE and LMP tumors (P =
.009); and between HOSE and high-grade serous cancers
(P = .001). These results demonstrated that DLEC1 was
downregulated in a majority of borderline and invasive epi-
thelial ovarian cancers.
DLEC1 Reexpression Reduced Tumor Growth
in Ovarian Cancer Cells
The growth-inhibitory effect of DLEC1 in ovarian cancer
was examined by anchorage-dependent colony formation
assay. Two ovarian cancer cell lines (OVCA429 and
OVCA432) were tested. After transfection of the full-length
DLEC1 cDNA or the vector alone into OVCA429 cells,
DLEC1 mRNA was detected at a significantly higher level
in DLEC1 transfectants compared with mock transfectants
(Figure 2A). Colony formation assay showed that the
number of colonies formed in DLEC1-expressing OVCA429
and OVCA432 cells was significantly reduced by 51.8%
and 41.1%, respectively, when compared to that of mock
transfectants (Figure 2, B and C). The results demonstrated
that DLEC1 reexpression reduces the growth of ovarian
cancer cells.
Concurrent Analysis of LOH and CNA of Chromosome 3
DLEC1 downregulation may be due to the loss of chro-
mosome 3p22.3. To prove it, both LOH and CNA on chro-
mosome 3 were analyzed in 11 human ovarian cancer cell
lines using the Affymetrix 10K SNP mapping array. An LOH
region spanning 3p22.2–3p23 was detected in 7 of 11
(63.6%) ovarian cancer cells. However, no copy number
change on the region was found in any ovarian cancer cell
line compared to that of normal HOSE cultures (Figure 3A).
By real-time quantitative PCR, no copy change of the DLEC1
locus (SHGC-170056) was detected in any of the ovarian
cancer cell lines (Figure 3B). We also performed LOH and
CNA studies on three primary ovarian tumor tissues (OVCA
tumors 633, 656, and 702). Although the LOH of chromo-
somes 3p22–3p23 was detected in an ovarian tumor tissue,
no chromosomal loss on 3p22.3 was observed in our CNA
data (Figure 3C). Therefore, our results demonstrated that
DLEC1 loci maintained two copies in ovarian cancer cell
lines and tissues. That will lead to our suggestion thatDLEC1
downregulation in ovarian tumors is not due to chromosomal
loss of 3p.
Promoter Hypermethylation and Histone Hypoacetylation
Contribute to DLEC1 Downregulation in Ovarian Cancer
Because CpG island was found in 5V UTR and exon 1 of
DLEC1 (Figure 4A), we hypothesized that promoter hyper-
methylation may be the mechanism used to repress DLEC1
expression in ovarian cancer. To test this hypothesis, the
methylation status of theDLEC1 promoter among HOSE and
ovarian cancer cell lines was evaluated by MSP. CpG
methylation was detected in the DLEC1 promoter in ovarian
cancer cell lines with reduced DLEC1 transcripts: complete
methylation of the DLEC1 promoter (only methylated alleles)
was detected in cell lines CaOV3, OVCA3, OVCA429,
OVCA432, OVCA633, SKOV3, and TOV112D, and partial
methylation (both methylated and unmethylated alleles) was
detected in cell lines DOV13, OVCA420, and OVCA433.
DLEC1 methylation was not detected in normal HOSE
cultures (HOSE2105, HOSE2170, HOSE2177, HOSE2107,
and HOSE0706) and DLEC1-expressing cancer cell lines
(MCAS and PEO4) (Figures 1A and 4A). DLEC1methylation
patterns were further confirmed by bisulfite sequencing on
several ovarian cancer cell lines. Dense DLEC1 methyla-
tion was observed in OVCA432, OVCA633, and OVCA433
cells; partial methylation was observed in OVCA420 cells;
and rare methylation was detected in MCAS and PEO4 cells
(Figure 4B).
In the treatment of ovarian cancer cell lines that showed
DLEC1 downregulation with demethylating agent (AZA),
90% (9 of 10; except the cell line DOV13) showed significant
upregulation of the DLEC1 transcript after AZA treatment
(Figure 5A). Partial demethylation of DLEC1 promoters was
also detected in representative ovarian cancer cell lines
(CaOV3 and OVCA3) after AZA treatment (Figure 5B).
These findings again confirmed that DLEC1 downregulation
is mediated by promoter hypermethylation.
DLEC1 methylation was also investigated in 14 high-
grade ovarian tumor tissues. For tumor tissues expressing
DLEC1 (G3S3-393), no CpG methylation was found in the
DLEC1 promoter. Among the 13 tumor tissues that showed
DLEC1 downregulation, 54% (7 of 13) demonstrated DLEC1
promoter methylation. However, 46% (6 of 13) showed
unmethylation on the DLEC1 promoter (Figure 5, C and D).
These results suggested that other epigenetic alterations
might contribute to DLEC1 downregulation in ovarian cancer.
Histone acetylation was suggested to be another pos-
sible epigenetic alteration contributing to DLEC1 down-
regulation [22]. To evaluate that, ovarian cancer cell lines
were treated with the histone deactylase (HDAC) inhibitor
Trichostain A (TSA). After TSA treatment, significant up-
regulation of DLEC1 was observed in 80% (8 of 10) of
ovarian cancer cell lines (DOV13, OVCA420, OVCA429,
OVCA432, OVCA433, OVCA633, SKOV3, and TOV112D)
(Figure 6A). By ChIP analysis, an enhanced association be-
tween acetylated histone (H3 and H4) and the DLEC1 pro-
moter was found in representative ovarian cancer cell lines
(DOV13, OVCA420, and OVCA433) (Figure 6B). These data
indicated that histone hypoacetylation is another epigenetic
mechanism used to suppress DLEC1 expression in ovar-
ian cancers.
Discussion
The short arm of chromosome 3 was thought to harbor
tumor-suppressor genes in human cancers. However, only
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Figure 1. (A) Relative quantification of DLEC1 mRNA in normal HOSE cell cultures and ovarian cancer cell lines. Experiments were performed in triplicate. DLEC1
downregulation was observed in ovarian cancer cell lines compared with HOSE cell lines (P = .027). The referent was HOSE2177, which was considered to have a
value of 1. (B) Relative quantification of DLEC1mRNA in HOSE samples and primary ovarian epithelial tumor tissues. DLEC1 expression was reduced in a majority
of primary ovarian tumors. The referent was HOSE1912, which was considered to have a value of 1. (C) Relative quantification of DLEC1 among HOSE tumors,
serous tumors of LMP, low-grade serous tumors, and high-grade serous tumors. The box is bounded above and below by the 75th and 25th percentiles, and the
median is indicated by the line in the box. Expression differences were obtained between 5 HOSE, 25 LMP, 6 low-grade, and 60 high-grade tumors by Kruskal-
Wallis test (P = .001).
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a limited number was found to be related to epithelial ovarian
cancers. Here, we investigated whether DLEC1 (located on
3p22.3) was one of the candidate tumor-suppressor genes
in ovarian cancer.
The tumor-suppressing properties of DLEC1 were sup-
ported by studies showing aberrant expression of DLEC1 in
several human cancers, including lung, esophageal, and
renal tumors [15]. By sequence analysis, six alternatively
spliced transcripts of DLEC1 were identified in normal lung,
esophageal, and kidney tissues. However, all these six alter-
ative spliced transcripts were likely to encode nonfunctional
proteins. In cancer cell lines and tumor samples, DLEC1
expression patterns were varied. Some tumor samples
did not express any DLEC1 transcripts, whereas some of
them expressed aberrant, but not normal, transcripts [15].
In the present study, our primer sets were flanking exons 1
and 2 of DLEC1, which could detect all alterative tran-
scripts of the gene. We found that the expression level of
DLEC1 transcripts (including the normal DLEC1 transcript)
in ovarian cancer cell lines and tumor tissues was lower
than that in normal HOSE samples. That would lead to
our hypothesis that DLEC1 may be the tumor suppressor
in ovarian cancer.
To prove this hypothesis, DLEC1 overexpression and
anchorage-dependent colony formation assay were tested
on two ovarian cancer cell lines. The number of colonies
formed in DLEC1 transfectants was significantly lower than
that of mock transfectants, which showed that DLEC1 sup-
pressed the growth of ovarian cancer cells. Although we
noted that the overexpression of any gene in the cells could
cause growth suppression, we suggest that DLEC1 exhibits
a certain feature as a tumor suppressor in ovarian cancer
because a similar tumor-suppressing effect of DLEC1 was
also reported in lung, esophageal, renal, and nasopharyn-
geal cancers [15] (K. W. Lo, personal communication). To
further confirm the tumor-suppressor role of DLEC1, DLEC1
knockdown experiments by siRNA in normal HOSE cell lines
are necessary.
Loss of chromosome 3p22.3 was found in several tumors,
including cervical, renal, lung, and breast tumors [23,24].
Surprisingly, we have not found any loss of chromosome
3p22.3 in ovarian cancer cell lines and tumor tissues, al-
though LOH was detected in some samples. Our previous
study also demonstrated that no chromosome 3p22.3 copy
number change was found in microdissected serous ovarian
cancer tissues using a cDNA microarray platform [25]. Thus,
our CNA data showed that two copies of the DLEC1 gene
are maintained in ovarian cancer. It is possible to speculate
that DLEC1 downregulation is not due to chromosomal loss
of 3p22.3.
Epigenetic modifications on the promoter are related to
transcriptional regulation of the gene. Promoter hyper-
methylation is associated with transcriptional repression of
tumor-suppressor and cancer-related genes [26]. Aberrant
methylation of multiple cancer-related genes (such asBRCA,
RASSF1A, and OPCML) is a frequent event in epithelial
cancer compared with normal ovarian surface epithelium
[27–29]. Among those methylated genes, promoter methyl-
ation of the hMLH1 is critical to the loss of hMLH1 expression
and drug resistance in ovarian cancer [30]. In this study, we
have clearly demonstrated that the loss of DLEC1 expres-
sion in ovarian cancer is closely associated with promoter
hypermethylation. Because hMLH1 is also located on chro-
mosome 3p22.3, it is possible to speculate that promoter
hypermethylation is a critical mechanism used to silence
tumor-suppressor genes, which are located on 3p22.3 in
ovarian cancer.
Histone hypoacetylation is another mechanism that coop-
erates with DNA methylation in gene silencing [22]. Two
cancer-related genes TMS1 and PACE4 are also silenced
Figure 2. (A) Relative quantification of DLEC1 after full-length DLEC1 cDNA
transfection in the OVCA429 cell line. The DLEC1 mRNA level was signifi-
cantly higher in transfectant cells with pcDNA3.1+/DLEC1 when compared
to empty vector control (pcDNA3.1+) and water control in the Lipofectamine
transfection experiment (H2O control). The referent was HOSE2177, which
was considered to have a value of 1. (B) Anchorage-dependent colony
formation assay using the OVCA429 cell line. The photograph showed dishes
containing cells transfected either with DLEC1 (pcDNA3.1+/DLEC1) or with an
empty vector (pcDNA3.1+). After G418 selection for 10 days, cells were
stained and counted. (C) The number of colonies formed between transfectant
cells with DLEC1 (pcDNA3.1+/DLEC1) and an empty vector (pcDNA3.1+).
Each experiment was repeated thrice. The fraction of colonies (in percent)
in each disc compared with vector-transfected cells is indicated.
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in ovarian cancer by DNA methylation and histone hypo-
acetylation [31,32]. In this study, restoration of DLEC1 ex-
pression after histone deacetylase inhibitor treatment and
enhanced association between acetylated histones (H3
and H4) and the DLEC1 promoter indicate that histone
hypoacetylation is also involved in DLEC1 downregulation
in ovarian cancer cells. Because several histone deacetylase
inhibitors were found to exhibit antiproliferative activity and to
Figure 3. (A) Concurrent analysis of LOH and CNA on chromosome 3 in 11 ovarian cancer cell lines. Left panel: SNP markers of chromosome 3 examined in this
study. Middle panel: Results of the LOH study: each column represents one cell line, and each row represents an SNP marker. Color codes: blue for LOH, yellow
for retained, grey for uninformative, and white for no call. Right panel: The CNA study: copy number changes were represented by different intensities of red. The
arrow indicates the location of the DLEC1 gene. (B) Analysis of the copy number on DLEC1 loci by quantitative PCR. The STS marker SHGC-170056 on
chromosomal 3p22.3 was analyzed and normalized by microsatellite marker D2S385 and Line-1 locus. PBL DNA from healthy subjects. No deletion on SHGC-
170056 was found in HOSE and ovarian cancer cell lines. (C) Concurrent analysis of LOH and CNA on chromosome 3 in three primary ovarian tumor tissues.
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Figure 4. (A) Promoter methylation of DLEC1 in HOSE and ovarian cancer cell lines. The schematic diagram illustrated a CpG island on the DLEC1 promoter. Grey
box, exon 1 of the DLEC1 gene; vertical lines, CpG dinucleotides; (+1), transcription initiation site; solid black line, CpG island; arrows, primer locations for MSP.
The PCR products in lane M indicate the presence of methylated alleles; the PCR products in lane U show the presence of unmethylated alleles. In vitromethylated
DNA served as methylated control. (B) Genomic bisulfite sequencing of the DLEC1 5 V CpG island in six representative ovarian cancer cell lines. Eighteen CpG
dinucleotides were analyzed in the 5V promoter and exon 1 of the DLEC1 gene (represented as 18 columns of circles). Eight to 10 sequences were analyzed for
each sample. Each row represents an individual sequence. Open circles, unmethylated CpG sites; closed circles, methylated CpG sites. mRNA expression levels
of DLEC1 on those six ovarian cancer cell lines are indicated on the right panel.
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induce apoptosis in human ovarian cancer cells [33], we sug-
gest that the restoration of tumor-suppressor genes, such
as DLEC1 and others, by HDAC inhibitors might contribute
to antitumor effects.
In conclusion, we have demonstrated the loss of DLEC1
expression in ovarian cancers and the suppression of ovar-
ian cancer cell growth by DLEC1 reexpression. The loss of
DLEC1 expression in ovarian cancers is related to promoter
Figure 5. (A) Relative quantification of DLEC1 in ovarian cancer cell lines after AZA treatment. Ninety percent (9 of 10) of ovarian cancer cell lines (except DOV13)
showed a significant upregulation of the DLEC1 transcript after AZA treatment. The referent was HOSE2177, which was considered to have a value of 1. (B) MSP
results of DLEC1 in representative ovarian cancer cell lines (CaOV3 and OVCA3) after AZA treatment. An unmethylated sequence was detected in AZA-treated
cells (1 M). (C) MSP results of the DLEC1 promoter in 14 high-grade ovarian tumor tissues. (D) The bar chart is combined with both relative quantification
of DLEC1 expression and methylation status of the DLEC1 promoter in primary ovarian tumor tissues. M represents detected DLEC1 promoter methylation;
U represents detected unmethylated DLEC1 promoter.
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hypermethylation and histone hypoacetylation, but not to loss
of chromosome 3p22.3.
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